Business
OncBioMune Phase 2 Prostate Cancer Trial in Mexico Key to Expedited Commercialization
OncBioMune Phase 2 Prostate Cancer Trial in Mexico Key to Expedited Commercialization.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n\n\nOncBioMune Phase 2 Prostate Cancer Trial in Mexico Key to Expedited Commercialization\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncBioMune Phase 2 Prostate Cancer Trial in Mexico Key to Expedited Commercialization\nPR Newswire\nBATON ROUGE, LA, June 3, 2016\n\n\n\nBy Sara Bowman, Senior Staff Writer, Online Media Group, Inc.\n\n\n\nBATON ROUGE, LA, June 3, 2016 /PRNewswire/ - Everyone knows clinical trials can be long, expensive and onerous, so finding any expedited pathway is a bonus for a company and its shareholders.  For OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP), a partnership with Vitel Laboratorios in Mexico could be a valuable shortcut towards seeing if its prostate cancer vaccine can be commercialized in an abbreviated fashion.\n\nThe two companies struck a deal to enter a joint venture, being coined \"OncBioMune Mexico S.A. de C.V.,\" only six weeks ago for the purpose of developing OncBioMune's vaccine, ProscaVax, in Mexico and throughout Latin America.  Per the latest press, the JV will also hold commercialization rights in Europe, China and the rest of the world outside the U.S. as well.  ProscaVax is already patented in about 50 countries worldwide.\n\nVitel has a well-established presence in the Mexican pharmaceutical space and overseas ties and has used their experience to move quickly with signing principal investigators for a Phase 2 trial and set up key meetings with regulatory authorities, similar to the FDA process in the U.S.  For the protocol, OncBioMune was able to leverage an ongoing Phase 1 trial in California evaluating ProscaVax in recurrent prostate cancer patients and preparatory work being done for a separate Phase 2 trial planned to be hosted at Beth Israel Deaconess Medical Center and its hospital network on early-stage prostate cancer patients.\n\nThe principal investigators for the Phase 2 Mexican trial, which will evaluate ProscaVax in PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients, have green lighted the protocol with the final document expected to be submitte...